Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
August 05, 2024 16:05 ET
|
Terns Pharmaceuticals, Inc.
Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
August 01, 2024 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
July 29, 2024 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
June 21, 2024 18:30 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2024 16:10 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 30, 2024 08:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
May 17, 2024 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
May 13, 2024 08:05 ET
|
Terns Pharmaceuticals, Inc.
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for...
Terns Pharmaceuticals Announces Leadership Changes
May 08, 2024 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
May 07, 2024 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...